Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer

Clinical Cancer Research

Volumn 8, Issue 10, 2002, Pages 3226-3231

  Fox, William D ^a   Higgins, Brian ^a   Maiese, Krista M ^a   Drobnjak, Marija ^b   Cordon Cardo, Carlos ^b   Scher, Howard I ^b   Agus, David B ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANDROGEN; PACLITAXEL; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER MODEL; CONTROLLED STUDY; CYTOSTASIS; DOSE RESPONSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; XENOGRAFT;

ANDROGENS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENDOTHELIAL GROWTH FACTORS; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; PROSTATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036795180     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Ferrara, N. The role of vascular endothelial growth factor in the regulation of blood vessel growth. In: R. J. Bicknell, C. E. Lewis, and N. Ferrara (eds.), Tumor Angiogenesis, pp. 185-199. New York: Oxford University Press, 1997.
2. Darland, D. C. Blood vessel maturation: vascular development comes of age. J. Clin. Investig., 103: 157-158, 1999.
3. Folkman, J., and Shing, Y. Angiogenesis. J. Biol. Chem., 267: 10931-10934, 1992.
4. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82: 4-6, 1990.
5. Klagsbrun, M., and D'Amore, P. A. Regulators of angiogenesis. Annu. Rev. Physiol., 53: 217-239, 1991.
6. Sordello, S., Bertrand, N., and Plouet, J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem. Biophys. Res. Commun., 251: 287-290, 1998.
7. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (Lond.), 362: 841-844, 1993.
8. Joseph, I. B., and Isaacs, J. T. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res., 57: 1054-1057, 1997.
9. Franck-Lissbrant, I., Haggstrom, S., Damber, J. E., and Bergh, A. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats [see comments]. Endocrinology, 139: 451-456, 1998.
10. Bigler, S. A., Deering, R. E., and Brawer, M. K. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum. Pathol., 24: 220-226, 1993.
11. Vesalainen, S., Lipponen, P., Talja, M., Alhava, E., and Syrjanen, K. Tumor vascularity and basement membrane structure as prognostic factors in T1-2MO prostatic adenocarcinoma. Anticancer Res., 14: 709-714, 1994.
12. Weidner, N., Carroll, P. R., Flax, J., Blumenfeld, W., and Folkman, J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol., 143: 401-409, 1993.
13. Weidner, N., Folkman, J., Pozza, F., Bevilacqua, P., Allred, E. N., Moore, D. H., Meli, S., and Gasparini, G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma [see comments]. J. Natl. Cancer Inst., 84: 1875-1887, 1992.
14. Kitadai, Y., Haruma, K., Tokutomi, T., Tanaka, S., Sumii, K., Carvalho, M., Kuwabara, M., Yoshida, K., Hirai, T., Kajiyama, G., and Tahara, E. Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin. Cancer Res., 4: 2195-2200, 1998.
15. Borre, M., Nerstrom, B., and Overgaard, J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin. Cancer Res., 6: 1882-1890, 2000.
16. Sweeney, C. J., Miller, K. D., Sissons, S. E., Nozaki, S., Heilman, D. K., Shen, J., and Sledge, G. W., Jr. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res., 61: 3369-3672, 2001.
17. Pretlow, T. G., Wolman, S. R., Micale, M. A., Pelley, R. J., Kursh, E. D., Resnick, M. I., Bodner, D. R., Jacobberger, J. W., Delmoro, C. M., Giaconia, J. M., et al. Xenografts of primary human prostatic carcinoma. J. Natl. Cancer Inst., 85: 394-398, 1993.
18. Nagabhushan, M., Miller, C. M., Pretlow, T. P., Giaconia, J. M., Edgehouse, N. L., Schwartz, S., Kung, H. J., de Vere White, R. W., Gumerlock, P. H., Resnick, M. I., Amini, S. B., and Pretlow, T. G. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res., 56: 3042-3046, 1996.
19. Cheng, L., Sun, J., Pretlow, T. G., Culp, J., and Yang, N-S. CWR22 xenograft as an ex vivo human tumor model for prostate cancer gene therapy. J. Natl. Cancer Inst., 88: 607-611, 1996.
20. Robinson, D., He, F., Pretlow, T., and Kung, H. J. A tyrosine kinase profile of prostate carcinoma. Proc. Natl. Acad. Sci. USA, 93: 5958-5962, 1996.
21. Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., Krummen, L., Winkler, M., and Ferrara, N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res., 57: 4593-4599, 1997.
22. Petit, A. M., Rak, J., Hung, M. C., Rockwell, P., Goldstein, N., Fendly, B., and Kerbel, R. S. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol., 151: 1523-1530, 1997.
23. Borgstrom, P., Bourdon, M. A., Hillan, K. J., Sriramarao, P., and Ferrara, N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate, 35: 1-10, 1998.
24. Agus, D. B., Cordon-Cardo, C., Fox, W. D., Drobnjak, M., Golde, D. W., and Scher, H. I. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J. Natl. Cancer Inst., 91: 1869-1876, 1999.
25. Agus, D. B., Scher, H. I., Higgins, B., Fox, W. D., Heller, G., Fazzari, M., Cordon-Cardo, C., and Golde, D. W. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res., 59: 4761-4764, 1999.
26. Kollermann, J., and Helpap, B. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. Am. J. Clin. Pathol., 116: 115-121, 2001.
27. Chen, H. J., Treweeke, A. T., Ke, Y. Q., West, D. C., and Toh, C. H. Angiogenically active vascular endothelial growth factor is overexpressed in malignant human and rat prostate carcinoma cells. Br. J. Cancer, 82: 1694-1701, 2000.
28. Jones, A., Fujiyama, C., Turner, K., Fuggle, S., Cranston, D., Bicknell, R., and Harris, A. L. Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. Br. J. Urol., 85: 276-280, 2000.
29. Ferrer, F. A., Miller, L. J., Andrawis, R. I., Kurtzman, S. H., Albertsen, P. C., Laudone, V. P., and Kreutzer, D. L. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells [see comments]. J. Urol., 157: 2329-2333, 1997.
30. Jackson, M. W., Bentel, J. M., and Tilley, W. D. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J. Urol., 157: 2323-2328, 1997.
31. Mallery, S. R., Lantry, L. E., Laufman, H. B., Stephens, R. E., and Brierley, G. P. Modulation of human microvascular endothelial cell bioenergetic status and glutathione levels during proliferative and differentiated growth. J. Cell. Biochem., 53: 360-372, 1993.
32. Hahn, D., Simak, R., Steiner, G. E., Handisurya, A., Susani, M., and Marberger, M. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. J. Urol., 164: 506-510, 2000.
33. Ferrer, F. A., Miller, L. J., Lindquist, R., Kowalczyk, P., Laudone, V. P., Albertsen, P. C., and Kreutzer, D. L. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology, 54: 567-572, 1999.
34. Soker, S., Kaefer, M., Johnson, M., Klagsbrun, M., Atala, A., and Freeman, M. R. Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am. J. Pathol., 159: 651-659, 2001.
35. Dor, Y., Porat, R., and Keshet, E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am. J. Physiol., 280: C1367-C1374, 2001.
36. Clauss, M., and Schaper, W. Vascular endothelial growth factor: a jack-of-all-trades or a nonspecific stress gene? Circ. Res., 86: 251-252, 2000.
37. Agus, D. B., Akita, R. W., Fox, W. D., Lofgren, J. A., Higgins, B., Maiese, K., Scher, H. I., and Sliwkowski, M. X. A potential role for activated HER-2 in prostate cancer. Semin. Oncol., 27: 76-83; discussion 92-100, 2000.
38. Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., and Slamon, D. J. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol., 16: 2659-2671, 1998.
39. Shin, D. M., Donato, N. J., Perez-Soler, R., Shin, H. J., Wu, J. Y., Zhang, P., Lawhorn, K., Khuri, F. R., Glisson, B. S., Myers, J., Clayman, G., Pfister, D., Falcey, J., Waksal, H., Mendelsohn, J., and Hong, W. K. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res., 7: 1204-1213, 2001.
40. Inoue, K., Slaton, J. W., Perrotte, P., Davis, D. W., Bruns, C. J., Hicklin, D. J., McConkey, D. J., Sweeney, P., Radinsky, R., and Dinney, C. P. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res., 6: 4874-4884, 2000.
41. Stewart, R. J., Panigrahy, D., Flynn, E., and Folkman, J. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J. Urol., 165: 688-693, 2001.
42. Joseph, I. B., Nelson, J. B., Denmeade, S. R., and Isaacs, J. T. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin. Cancer Res., 3: 2507-2511, 1997.
43. Margolin, K., Gordon, M. S., Holmgren, E., Gaudreault, J., Novotny, W., Fyfe, G., Adelman, D., Stalter, S., and Breed, J. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol., 19: 851-856, 2001.